PanDNA® is the molecular technology that drives PancraGEN®. It identifies cumulative DNA abnormalities in pancreatic cysts. Using well-established molecular markers, PanDNA® can help inform patient management when used in the context of clinical features, imaging, and cytology results.

DNA Abnormalities:

Tumor Suppressor Gene Panel (Loss of Heterozygosity)

VHL, OGG1

3p

PTEN, MXI1

10q

TP53

17p

SMAD4, DCC

18q

CDKN2A

9p

RNF43, NME1

17q

PSEN2, TFF1

21q

CMM1v

1p

MCC, APC

5q

NF2

22q

    

Oncogene (Point Mutations)

KRAS

Codons 12, 13

GNAS

Codon 201

Elevated DNA Quantity

Key Components of Report

  • Summary of Molecular Results
  • Specific Molecular Results
  • Details of molecular results and what they could mean in clinical context